The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions

Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions

August 6, 2021 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“Prior authorization is the single most detrimental factor to patient therapy because it can delay treatment initiation and/or continuity of care, which in turn may negatively impact patient outcomes,” says Georgia Bonney, CMPM, CRMS, CRHC, practice manager for Virginia Rheumatology Clinic, Chesapeake. “In a system where we are striving to reduce disease activity and payers want us to focus on quality metrics to prove our worth, the prior authorization process can feel like a detour to failure.”

You Might Also Like
  • Tips for Smoothing the Time-Consuming Prior Authorization Process
  • Principles Would Streamline Prior Authorization Processes
  • Reminder: How to Handle Part D Prior Authorization Requests
Explore This Issue
August 2021
Also By This Author
  • The Smartphone as Diagnostic Tool
Georgia Bonney

Ms. Bonney

Prior authorization is part of a broader set of cost control measures (e.g., step therapy, forced switching, restrictive formularies, specialty tiers, and substitution of biosimilars or generic drugs) implemented by payers, pharmacy benefit managers (PBMs) or other agents engaged to manage healthcare benefits, says Christopher Phillips, MD, a rheumatologist in solo practice in Paducah, Ky., and chair of the Insurance Subcommittee to the ACR’s Committee on Rheumatologic Care. The rationale is to prevent wasteful healthcare spending, but in reality prior authorization often serves as a delaying tactic, making patients and doctors jump through hoops before needed drugs are approved.

Dr. Chris Phillips

Dr. Phillips

“We’ve been subjected to prior authorization for years, but it has become increasingly more burdensome,” says Dr. Phillips.

Early in the COVID-19 pandemic, some insurers suspended prior authorization requirements. But now it’s back to business as usual, and with increasing access to nonemergent medical care, insurers are raising new obstacles to try to limit their financial exposure.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“In the field of rheumatology, it’s possibly even more burdensome than for other medical specialties,” says Dr. Phillips. “Not surprisingly, all of our newer, more expensive drugs need prior authorization. But in our office, we’ve seen that even generic NSAIDs [non-steroidal anti-inflammatory drugs], methotrexate or prednisone might require a prior authorization.”

Dr. Phillips’ practice, like many others, employs the equivalent of a full-time staff person dedicated just to working through prior authorization and similar reviews for prescribed drugs. Most often, these drugs eventually get approved, but that can take weeks or, occasionally, months. “Three months later,” he says, “we see the patient again, assuming they’ve been taking the medication we ordered all that time, and find out they weren’t getting it.”

Impact on Practices

In a 2018 AMA survey of 1,000 physicians, three-quarters of respondents reported that prior authorization hassles can lead to patients abandoning treatments and 91% said it has delayed their patients’ access to care.1 They also reported their prior authorization burden had increased over the previous five years.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Legislation & Advocacy, Practice Management Tagged With: Advocacy, prior authorizationIssue: August 2021

You Might Also Like:
  • Tips for Smoothing the Time-Consuming Prior Authorization Process
  • Principles Would Streamline Prior Authorization Processes
  • Reminder: How to Handle Part D Prior Authorization Requests
  • UnitedHealthcare Retires Fax Numbers Used for Prior Authorization Requests

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)